Mirador Capital Partners LP Grows Position in Pfizer Inc. $PFE

by · The Cerbat Gem

Mirador Capital Partners LP lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 31.6% in the second quarter, HoldingsChannel.com reports. The firm owned 48,575 shares of the biopharmaceutical company’s stock after acquiring an additional 11,662 shares during the quarter. Mirador Capital Partners LP’s holdings in Pfizer were worth $1,177,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Trust Co of the South grew its holdings in shares of Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 441 shares during the period. William B. Walkup & Associates Inc. lifted its stake in Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after acquiring an additional 454 shares in the last quarter. Members Trust Co lifted its stake in Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 467 shares in the last quarter. Sutton Place Investors LLC lifted its stake in Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 472 shares in the last quarter. Finally, Fragasso Financial Advisors Inc lifted its stake in Pfizer by 2.2% during the 2nd quarter. Fragasso Financial Advisors Inc now owns 22,460 shares of the biopharmaceutical company’s stock worth $544,000 after acquiring an additional 480 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Finally, Bank of America increased their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.12.

Get Our Latest Stock Analysis on Pfizer

Pfizer Trading Down 0.4%

NYSE:PFE opened at $23.88 on Wednesday. The stock’s 50 day moving average price is $24.73 and its 200 day moving average price is $24.25. The company has a market capitalization of $135.77 billion, a PE ratio of 12.70, a P/E/G ratio of 0.85 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).